Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.67 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GGT1 | P19440 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL22972824 | 0.90 | KDM4E (0.73) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL27414704 | 0.89 | KDM4E (0.67) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL11799149 | 0.88 | KDM4E (0.65) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL11791031 | 0.85 | KDM4E (0.65) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Mesalamine SCHEMBL27914514 | 0.84 | ALDH1A1 (0.67) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL4588777 | 0.84 | KDM4E (0.73) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL473691 | 0.84 | KDM4E (0.83) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL21647369 | 0.84 | KDM4E (0.83) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| Aspirin SCHEMBL11181820 | 0.84 | KDM4E (0.83) | KDM4EHSD17B10HPGDALDH1A1PTGS2 | |
| SCHEMBL8699559 | 0.83 | KDM4E (0.73) | KDM4EHSD17B10HPGDALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040724-B1 | BIOTHERAPEUTIC COMPOSITIONS COMPRISING PROBIOTIC ESCHERICHIA COLI AND METRONIDAZOLE AND USES THEREOF | BIOBALANCE LLC (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090252708-A1 | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof | BIOBALANCE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2040724-A2 | BIOTHERAPEUTIC COMPOSITIONS COMPRISING PROBIOTIC ESCHERICHIA COLI AND USES THEREOF | BIOBALANCE LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007136719-A2 | BIOTHERAPEUTIC COMPOSITIONS COMPRISING PROBIOTIC ESCHERICHIA COLI AND USES THEREOF | BIOBALANCE LLC (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252708-A1 | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof | IL17A, MRPS27, MRPL37 | PTGS2 1270/4885PTGS1 892/4885KDM4E 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.